Neurológia pre prax 2/2019
The risk of developing malignant tumors in the modern treatment of multiple sclerosis: a review of the literature
Treatment of multiple sclerosis with new generation drugs is a long-term treatment, resulting in monitoring and treatment as well as the risk of serious late side effects such as secondary (induced) malignant tumours. An increased risk of malignancy during immunosuppressive therapy has been demonstrated in patients treated with cytotoxic agents mitoxantrone (MX), methotrexate (MTX) and cyclophosphamide (CFA), immunosuppressive as azathioprine (AZA), however, this assumption has not been confirmed in more modern treatments. We present an overview of Cladribine, Alemtuzumab, and Teriflunomide , where data are not yet unambiguously suspected or rebutted. Therefore, there is a need for careful pre-screening of the parties for the presence of tumors prior to start of this treatment due to a worse prognosis of malignancy and multiple sclerosis and for careful monitoring of patients and reports of all and late potential adverse events treatment because the monitoring period is still short.
Keywords: multiple sclerosis, modern treatment, risk of development cancer
